Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 324

1.

Vasopressin, copeptin, and renal concentrating capacity in patients with autosomal dominant polycystic kidney disease without renal impairment.

Zittema D, Boertien WE, van Beek AP, Dullaart RP, Franssen CF, de Jong PE, Meijer E, Gansevoort RT.

Clin J Am Soc Nephrol. 2012 Jun;7(6):906-13. doi: 10.2215/CJN.11311111. Epub 2012 Apr 19.

2.

Autosomal dominant polycystic kidney disease is associated with central and nephrogenic defects in osmoregulation.

Ho TA, Godefroid N, Gruzon D, Haymann JP, Maréchal C, Wang X, Serra A, Pirson Y, Devuyst O.

Kidney Int. 2012 Nov;82(10):1121-9. doi: 10.1038/ki.2012.225. Epub 2012 Jun 20.

PMID:
22718190
3.

Copeptin, a surrogate marker of vasopressin, is associated with disease severity in autosomal dominant polycystic kidney disease.

Meijer E, Bakker SJ, van der Jagt EJ, Navis G, de Jong PE, Struck J, Gansevoort RT.

Clin J Am Soc Nephrol. 2011 Feb;6(2):361-8. doi: 10.2215/CJN.04560510. Epub 2010 Oct 7.

4.

Urine and plasma osmolality in patients with autosomal dominant polycystic kidney disease: reliable indicators of vasopressin activity and disease prognosis?

Casteleijn NF, Zittema D, Bakker SJ, Boertien WE, Gaillard CA, Meijer E, Spithoven EM, Struck J, Gansevoort RT.

Am J Nephrol. 2015;41(3):248-56. doi: 10.1159/000382081. Epub 2015 Apr 25.

5.

Bully renal cysts knock down urine-concentrating capacity in the early rounds.

Grantham JJ.

Clin J Am Soc Nephrol. 2012 Jun;7(6):875-7. doi: 10.2215/CJN.03720412. Epub 2012 May 10. No abstract available.

6.

Kidney function and plasma copeptin levels in healthy kidney donors and autosomal dominant polycystic kidney disease patients.

Zittema D, van den Berg E, Meijer E, Boertien WE, Muller Kobold AC, Franssen CF, de Jong PE, Bakker SJ, Navis G, Gansevoort RT.

Clin J Am Soc Nephrol. 2014 Sep 5;9(9):1553-62. doi: 10.2215/CJN.08690813. Epub 2014 Jul 3.

7.

Copeptin, a surrogate marker for vasopressin, is associated with kidney function decline in subjects with autosomal dominant polycystic kidney disease.

Boertien WE, Meijer E, Zittema D, van Dijk MA, Rabelink TJ, Breuning MH, Struck J, Bakker SJ, Peters DJ, de Jong PE, Gansevoort RT.

Nephrol Dial Transplant. 2012 Nov;27(11):4131-7. doi: 10.1093/ndt/gfs070. Epub 2012 Apr 20.

8.

Relationship of copeptin, a surrogate marker for arginine vasopressin, with change in total kidney volume and GFR decline in autosomal dominant polycystic kidney disease: results from the CRISP cohort.

Boertien WE, Meijer E, Li J, Bost JE, Struck J, Flessner MF, Gansevoort RT, Torres VE; Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease CRISP.

Am J Kidney Dis. 2013 Mar;61(3):420-9. doi: 10.1053/j.ajkd.2012.08.038. Epub 2012 Oct 22.

9.

Apelin and copeptin: two opposite biomarkers associated with kidney function decline and cyst growth in autosomal dominant polycystic kidney disease.

Lacquaniti A, Chirico V, Lupica R, Buemi A, Loddo S, Caccamo C, Salis P, Bertani T, Buemi M.

Peptides. 2013 Nov;49:1-8. doi: 10.1016/j.peptides.2013.08.007. Epub 2013 Aug 21.

PMID:
23973863
10.

Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function.

Boertien WE, Meijer E, de Jong PE, ter Horst GJ, Renken RJ, van der Jagt EJ, Kappert P, Ouyang J, Engels GE, van Oeveren W, Struck J, Czerwiec FS, Oberdhan D, Krasa HB, Gansevoort RT.

Am J Kidney Dis. 2015 Jun;65(6):833-41. doi: 10.1053/j.ajkd.2014.11.010. Epub 2015 Jan 15.

PMID:
25600953
11.

A pilot clinical study to evaluate changes in urine osmolality and urine cAMP in response to acute and chronic water loading in autosomal dominant polycystic kidney disease.

Barash I, Ponda MP, Goldfarb DS, Skolnik EY.

Clin J Am Soc Nephrol. 2010 Apr;5(4):693-7. doi: 10.2215/CJN.04180609. Epub 2010 Feb 18.

12.

Water prescription in autosomal dominant polycystic kidney disease: a pilot study.

Wang CJ, Creed C, Winklhofer FT, Grantham JJ.

Clin J Am Soc Nephrol. 2011 Jan;6(1):192-7. doi: 10.2215/CJN.03950510. Epub 2010 Sep 28.

13.

Evaluation of renal tubular functions in convalescent phase of hemorrhagic fever with renal syndrome.

Kim GH, Han JS, Earm J, Jeon US, Kim YS, Ahn C, Kim S, Lee JS.

Am J Nephrol. 1998;18(2):123-30.

PMID:
9569954
15.

Soluble klotho and autosomal dominant polycystic kidney disease.

Pavik I, Jaeger P, Ebner L, Poster D, Krauer F, Kistler AD, Rentsch K, Andreisek G, Wagner CA, Devuyst O, Wüthrich RP, Schmid C, Serra AL.

Clin J Am Soc Nephrol. 2012 Feb;7(2):248-57. doi: 10.2215/CJN.09020911. Epub 2011 Dec 22.

16.

Urinary excretion of monocyte chemoattractant protein-1 in autosomal dominant polycystic kidney disease.

Zheng D, Wolfe M, Cowley BD Jr, Wallace DP, Yamaguchi T, Grantham JJ.

J Am Soc Nephrol. 2003 Oct;14(10):2588-95.

18.

Does increased water intake prevent disease progression in autosomal dominant polycystic kidney disease?

Higashihara E, Nutahara K, Tanbo M, Hara H, Miyazaki I, Kobayashi K, Nitatori T.

Nephrol Dial Transplant. 2014 Sep;29(9):1710-9. doi: 10.1093/ndt/gfu093. Epub 2014 Apr 15.

19.

An abnormal apelin/vasopressin balance may contribute to water retention in patients with the syndrome of inappropriate antidiuretic hormone (SIADH) and heart failure.

Blanchard A, Steichen O, De Mota N, Curis E, Gauci C, Frank M, Wuerzner G, Kamenicky P, Passeron A, Azizi M, Llorens-Cortes C.

J Clin Endocrinol Metab. 2013 May;98(5):2084-9. doi: 10.1210/jc.2012-3794. Epub 2013 Mar 20.

PMID:
23515451
20.

Increased activity of the renal kallikrein-kinin system in autosomal dominant polycystic kidney disease in rats, but not in humans.

Braun C, Kleemann T, Birck R, Hilgenfeldt U, Riester U, Tschöpe C, van der Woude FJ, Rohmeiss P.

Int Immunopharmacol. 2002 Dec;2(13-14):1949-56.

PMID:
12489808
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk